Figure 2
Changes in platelet count and hemoglobin in COMFORT-I. (Reprinted from Verstovsek S, et al. Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. Onco Targets Ther [published by Dove Press] [22]). Shown are mean percentage changes from baseline (BL) with standard errors in (A) platelet count and (B) hemoglobin over time. Final titrated dose was defined as the average daily dose during weeks 21–24. BID, twice a day.